FLASHNEWS:

Searle Company Targets Aggressive Expansion with New Product Launches and Market Diversification

Karachi: The Searle Company Limited (SEARL) unveiled its strategic roadmap for financial growth during a corporate briefing focused on its fiscal year 2026 results and the first quarter of fiscal year 2027. The company highlighted its efforts to navigate supply chain challenges, launch new products, and expand into emerging markets as key pillars of its strategy.

According to JS Global, Searle has shifted its supply chain strategy by reducing reliance on Indian imports, now sourcing 80-85% of its raw materials from China. This change allows the company flexibility in passing cost increases onto consumers, considering that approximately 80% of its portfolio comprises non-essential items. Notably, the company launched its semaglutide product in August 2026, achieving Rs100 million in sales within just 75 days—the fastest in its history. Management aims for Rs1 billion in sales from this product by January 2027 and seeks to capture a 20-25% share of Pakistan's GLP-1 market within the next year.

Searle's management anticipates improved margins on semaglutide, despite competitive pricing cuts. The company plans to drive growth through biologicals, including semaglutide, tirzepatide, and autoimmune products, and intends to localize more production of these items. Currently, exports constitute approximately 12% of sales, with Afghanistan contributing 40-50% of that figure. Despite trade disruptions, supplies to Afghanistan continue via alternative routes like the UAE and air shipments, while expansion efforts target new markets such as Uzbekistan, Cameroon, and Kenya.

Institutional sales account for roughly 10-12% of Searle's earnings, with Nuberol as the flagship product in this division. The company's leading brands include Nuberol, Extor, Peditral, Hydryllin, and Gravinate, with recent launches featuring Rexeva, Bilfaxin, and Tramal D. The management projects a 20% sales growth in fiscal year 2027.

Additionally, Searle has applied for US FDA approval, receiving an acknowledgment in response. The company is upgrading two plants, including its main F-319 facility, to comply with international regulatory standards. On a consolidated level, Searle's sales increased by 29% year-on-year to Rs36.8 billion, transforming a Rs1.4 billion loss in fiscal year 2025 to a Rs536 million profit in fiscal year 2026. This turnaround is attributed to deleveraging and lower interest rates, which slashed finance costs to Rs1.1 billion from Rs2.10 billion in fiscal year 2025. In the first quarter of fiscal year 2027, consolidated sales rose 15% year-on-year to Rs11.2 billion, with gross margins climbing to 57% and profit after tax (PAT) increasing by 31% year-on-year to Rs1.2 billion. Management expects to maintain gross margins at or above 57%, despite higher logistics costs being a potential risk.